HEALTHglobal
R1 starts up with $78M, aiming for a better kidney drug
Single source
Updated 2 hours ago
First seen March 18, 2026 07:07:01Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
The startup believes a pill it licensed from a Chinese biotech company could be more potent, and convenient to take, than existing treatments for a common complication of chronic kidney disease.